This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): EPI-hNE4, Depelestat, DX-890
Description: DX-890 is a highly potent and specific inhibitor of human neutrophil elastase (hNE). hNE is an enzyme produced as part of the inflammatory response and is implicated in the loss of lung function in patients with cystic fibrosis and other clinical conditions.
Deal Structure: Dyax and Debiopharm are partners on DX-890. Under the terms of their agreement (restructured in December 2005), Debiopharm has exclusive worldwide rights for the development, manufacture and commercialization of a native form of DX-890 in cystic fibrosis (CF) and acute respiratory distress syndrome (ARDS).
Dyax retains rights to milestones and royalties with respect to Debiopharm's DX-890 programs, as well as the exclusive worldwide rights to extended half-life versions of DX-890 for development, manufacturing and commercialization in other chronic pulmonary indications such as chronic obstructive pulmonary disease (COPD). Dyax receives a milestone payment upon execution of the agreement in connection with Debiopharm's recent initiation of Phase I clinical studies in ARDS patients.
Partners: Shire Pharmaceuticals Group PLC
Debio 9701 News
Pink Sheet Cystic Fibrosis Pipeline
Additional information available to subscribers only: